Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
Aura Biosciences' strong data, focus on an unmet medical need, and solid execution make it a compelling biotech investment. Learn more about AURA stock here.
Aura Biosciences reports positive Phase 2 end of study results evaluating AU-011 for early-stage choroidal melanoma
In a presentation at the Retina Society meeting in Lisbon, Portugal, Ivana Kim, MD, explained that AU-011 (Bel-Sar) demonstrated 80% tumor control rate, 90% visual acuity preservation, and a favorable safety profile.
Buy Rating for Aura Biosciences: Bel-sar’s Market Potential and Advantages in Choroidal Melanoma Treatment
Jonathan Wolleben, an analyst from JMP Securities, reiterated the Buy rating on Aura Biosciences Inc (AURA – Research Report). The
Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma
Aura Biosciences announces positive results from phase 2 end of study of bel-sar as a first-line treatment for early-stage choroidal melanoma: Boston Saturday, September 14, 2024,
Positive Phase II Bolsters Aura Bioscience’s Confidence in VDC-based Therapy for Ocular Melanomas
The therapy for early-stage choroidal melanomas preserved vision in 90% of patients with no serious treatment-related adverse effects.
Aura Biosciences Shares Jump in Premarket on Positive Phase 2 Ocular Cancer Treatment Results
Aura Biosciences shares rose Thursday morning in premarket trading after reporting positive study results for bel-sar, its ocular cancer treatment. The stock traded 7.5% higher ahead of the morning bell at $9.75 a share.
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
1 The Phase 2 results are a significant achievement considering the typically poor prognosis associated with choroidal melanoma, a rare and life-threatening ocular cancer, where there are no approved vision-preserving therapies to date. Highly Favorable ...
Aura Bio gains after mid-stage data for lead asset in ocular cancer
Aura Biosciences (NASDAQ:AURA) added ~8% in the premarket on Thursday after the company said its lead asset bel-sar (AU-011) showed an 80% tumor control rate in a Phase 2 trial for patients with early-stage choroidal melanoma,
Medscape12y
Current Treatment of Choroidal Melanoma
Choroidal melanoma is the most common primary intraocular malignancy in adults. Alternative treatment modalities have been proposed in recent years including enucleation, local resection ...
Zacks.com on MSN6d
Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study
Shares of Aura Biosciences AURA gained 7.9% on Sept. 12 after the company announced encouraging data from a phase II study ...
GlobalData on MSN16d
FDA grants fast track status to Innovent’s IBI363 for melanoma
Fast track status is a process that facilitates the development of assets addressing serious conditions with unmet medical ...
Cure Today14d
FDA to Speed Up Review of IBI363 for Advanced Melanoma
The Food and Drug Administration granted a fast track designation to IBI363 for patients with unresectable advanced or ...
Medscape1mon
Current Treatment of Choroidal Melanoma
Despite the highly successful treatment outcomes for achieving local tumor control, long-term survival rates for uveal melanoma and large choroidal melanomas in particular remain dismal because of ...